News

Small Molecule Innovator API CDMO Market to Hit $47.14 Billion by 2030 at 6.38% CAGR, Driven by Outsourcing Trends and Drug Innovation
CDMOs Expand Capabilities Amid Surge in Clinical Trials and Demand for Orphan Drugs and Novel TherapiesDublin, April 18, 2025 (GLOBE NEWSWIRE) -- The "Small Molecule Innovator API CDMO Market Size, ...
Cyprumed Enters License and Option Agreement with MSD for the Development of Oral Peptide Therapeutics
MSD obtains a Non-Exclusive License for Cyprumed’s delivery technology to develop oral peptide therapeuticsCyprumed will be eligible to receive ...
Business Wire14d
TME Pharma Provides Update on Resources Allocated to the Liquidity Contract With Invest Securities
BERLIN--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by ...
Morningstar15d
TME Pharma Provides Update on Resources Allocated to the Liquidity Contract With Invest Securities
TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME ...
MSNBC16d
Global pharma shares plunge over Trump tariff threat
Global drugmakers’ stocks dropped across the board today after U.S. President Donald Trump reiterated plans for a “major” tariff on pharmaceutical imports, threatening an interwoven supply ...
Business Insider16d
Royalty Pharma appoints Biohaven CEO Vlad Coric to board
Royalty Pharma (RPRX) announced the appointment of Vlad Coric to the company’s board of directors, effective immediately. Vlad Coric is the chairman and CEO of Biohaven (BHVN). Published first ...
PR Newswire17d
Innocan Pharma Broadens Intellectual Property Coverage for its Liposomal CBD Injection Across Asia and Announces Private Placement of Units
HERZLIYA, Israel and CALGARY, AB, April 7, 2025 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a ...
Yahoo Finance24d
Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia
COPENHAGEN, Denmark, March 31, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has submitted its New Drug Application (NDA) to the U.S. Food & Drug Administration ...
live.euronext27d
TME Pharma Provides Results of Fifth Exercise of Warrants Z
TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), ...
Yahoo Finance27d
TME Pharma Provides Results of Fifth Exercise of Warrants Z
BERLIN, March 28, 2025--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment ...
Morningstar28d
TME Pharma Provides Results of Fifth Exercise of Warrants Z
TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME ...